Clinical trials: Ovarian Cancer Risk
Cardiovascular Diseases
Reexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study
The full HER CROWN will be a prospective cohort study to propose a novel, women-specific cardiovascular risk score/ algorithm in the prediction of hard cardiovascular outcomes (myocardial infarction, unstable angina, coronary…
- Trial name
- HER-CROWN (NCT05632601)
- Testing
- PET scan
- Where
- Canada
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Ovarian Cancer, Fallopian Tube Cancer
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
- Trial name
- NCT05287451
- Testing
- RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Fallopian Tube Cancer
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube…
- Conditions
- Carcinoma, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01253681
- Testing
- AMG 386, paclitaxel and carboplatin
- Where
- 8 sites in Australia, Belgium and 1 more
- Volunteers
- 27 people
- Sponsor
- Amgen
Epithelial Ovarian Cancer
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Combination-type oral contraceptives (COCs) have been shown to significantly reduce the risk of invasive epithelial ovarian cancer (IEOC); this protective effect may be achieved to a large extent through COCs ability to reduce…
- Trial name
- NCT02477202
- Testing
- Mirena® intra-uterine device (IUD)
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Ovary Syndrome, Hypothalamic Amenorrhea
Body Fat as Determinant of Female Gonadal Dysfunction
Reproduction requires from women enough energy depots to warrant an adequate nutritional supply to the fetus. Hence, adipose tissue is able to communicate with female hypothalamic-pituitary-ovary axis.
- Trial name
- NCT03841981
- Testing
- Anthropometric and physical examination, Indirect calorimetry, accelerometer and seven-day dietary recall, Biochemical, hormonal and metabolic phenotyping
- Where
- Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Infertility and at High Risk of OHSS
Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk…
- Trial name
- NCT02022228
- Testing
- triptorelin, hCG
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chenshiling
Ovarian Cancer
NYU Ovarian Cancer Early Detection Program Blood and Genetics
Improving current strategies for detection of early stage disease can impact favorably on long-term survival of women with ovarian cancer.
- Trial name
- NCT00531778
- Where
- United States
- Volunteers
- 890 people
- Sponsor
- NYU Langone Health
Polycystic Ovary Syndrome
Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial
Polycystic ovary syndrome (PCOS) is associated with an increased cardiovascular risk. The aim of the study was to evaluate long-term effects of inositol on some cardiovascular risk factors in PCOS patients.
- Trial name
- NCT01574261
- Testing
- Inositol
- Where
- Italy
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Ovarian Cancer, Antiangiogenic-Associated Hypertension
Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
Antiangiogenic therapies like bevacizumab, have notably improved cancer treatment, including for gynecological cancers, by inhibiting the vascular endothelial growth factor and thus limiting tumor growth.
- Conditions
- Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab, Hypertension
- Trial name
- IATRO (NCT06515678)
- Testing
- arm A - angiotensin converting enzyme inhibitors (ACEi), arm B - calcium channel blockers (CCBs), arm R - angiotensin receptor blockers ARB
- Where
- 2 sites in France
- Volunteers
- 9,464 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Ovarian Cancer
The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer
This study plans to enroll 80 patients with locally advanced cervical cancer (stage IB-ⅣA) confirmed by histology or cytology (according to the 2018 FIGO staging standard), who are expected to receive surgical resection or…
- Trial name
- NCT06283875
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Breast Cancer, Colo-rectal Cancer
A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the…
- Conditions
- Breast Cancer, Colo-rectal Cancer, Ovarian Cancer, Melanoma (Skin Cancer)
- Trial name
- PRO-ACTIVE (NCT07469709)
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Ovarian Cancer Risk, Risk-reducing Surgery
Why do Oral Contraceptives Prevent Ovarian Cancer?
Use of oral contraceptives (OCs) reduces a woman's risk of ovarian cancer very significantly and the protective effect continues for at least 25 years after use of OCs is stopped; the mechanisms of how this occurs are not…
- Conditions
- Ovarian Cancer Risk, Risk-reducing Surgery, Fallopian Tube Fimbriae, Ovarian Cortical Inclusion Cysts
- Trial name
- NCT02155777
- Testing
- OrthoNovum 1/35
- Where
- 3 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- University of Michigan
Polycystic Ovary Syndrome
Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome
To evaluate long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin alone and DRSP/EE plus metformin on some cardiovascular risk factors in hyperinsulinemic PCOS patients
- Trial name
- NCT01581814
- Testing
- Metformin, Yasmin;, Metformin plus Yasmin
- Where
- Italy
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Ovarian Cancer
Targeted Physical Activity to Improve Mobility and Falls Risk in Women Living With Ovarian Cancer
This study will explore the feasibility (suitability), efficacy (research-setting outcomes), and participant satisfaction of a virtually-supervised 12-week exercise and diet intervention for women with ovarian cancer.
- Trial name
- BE-BALANCED (NCT04911114)
- Testing
- Be-Balanced
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00253539
- Testing
- arzoxifene hydrochloride, tamoxifen citrate
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Hereditary Breast and Ovarian Cancer Syndrome
Women at Risk of Breast Cancer and OLFM4
Does the olfactomédine provide an help to limit the number of false positives in the overall imaging balance and limit the number of unnecessary biopsies?
- Trial name
- NCT02653105
- Testing
- OLFM4
- Where
- 4 sites in France
- Volunteers
- 150 people
- Sponsor
- Institut Cancerologie de l'Ouest
Polycystic Ovary Syndrome
Oral Contraceptive and Cardiovascular Risk in PCOS
Oral contraceptive therapy is routinely used for the treatment of menstrual disturbances of patients with polycystic ovary syndrome (PCOS).
- Trial name
- NCT00593294
- Testing
- Physical exercise, OC - Drospirenone plus Ethynylestradiol, Vitamin, polyvitamins tablets
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federico II University
Breast Cancer, Ovarian Cancer
Guilford Genomic Medicine Initiative (GGMI)
Genomic medicine, using genetic information to improve health outcomes, is heralded as the answer to rising medical costs by focusing on prevention and tailored care.
- Conditions
- Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
- Trial name
- GGMI (NCT01372553)
- Where
- United States
- Volunteers
- 1,184 people, healthy volunteers welcome
- Sponsor
- The Moses H. Cone Memorial Hospital
Polycystic Ovary Syndrome
Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS
A prospective study to determine the metabolic effects of the contraceptive vaginal ring among overweight and obese women with polycystic ovary syndrome (PCOS).
- Trial name
- RING-PCOS (NCT04257500)
- Testing
- Etonogestrel/ethinyl estradiol vaginal ring
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andrea Roe, MD, MPH